Definitive Contract 75A50120C00009

This is a sole-source contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Ridgeback Biotherapeutics LP for the development and manufacturing of the monoclonal antibody treatment mAb114 for Ebola virus disease (EVD). The contract has a ceiling value of $159,990,035.88 and a period of performance through July 31, 2023. It was awarded on March 19, 2020 as a cost-plus-fixed-fee definitive contract. The contract was awarded without a set-aside designation. The contract supports efforts necessary to submit a Biologics License Application for mAb114 to the U.S. Food and Drug Administration by July 2020, including manufacturing to augment the existing government supply of the treatment.